OP-ED: FUNDING ROADBLOCKS CREATING DIGITAL HEALTH INEQUITY Beyond just clinical: Making the case for a pivot in reimbursement by Australian Government
With
Helen Souris,
CEO and Executive Director
Cardihab &
Board Member
Medical Technology Association of Australia (MTAA)
OP ED SEGMENT
Filmed in Sydney | June 2026
Helen Souris, CEO and Executive Director of Cardihab and Chair of the Digital Health Advisory Group at the Medical Technology Association of Australia (MTAA), highlights the significant gap in cardiac rehabilitation access across Australia. Despite the proven benefits of cardiac rehabilitation in improving survival, quality of life, and reducing hospital admissions, around 80% of eligible patients do not receive this care, with access rates even lower in regional and rural communities.
Cardihab was established as a digital health company originating from CSIRO research and has spent the past decade developing a digital therapeutic solution for cardiac rehabilitation.
Delivered through a clinically supervised software platform, the program enables patients to access rehabilitation remotely, removing barriers associated with travel and face-to-face attendance. The platform is registered with the Therapeutic Goods Administration (TGA) as a Class IIa medical device, reflecting its compliance with rigorous clinical and regulatory standards.
Over ten years, Cardihab has built a substantial evidence base, including randomised controlled trials and real-world studies. Independent research has demonstrated improvements in patient outcomes, quality of life, and cost-effectiveness, with the program outperforming traditional alternatives in most evaluated scenarios. As a result, the majority of private health insurers now support access to the platform, while statewide implementation has been achieved through partnerships such as the Tasmanian Health Service.
Despite these successes, Souris identifies funding as the primary barrier to broader adoption within the public health system. She argues that Australia already possesses the technology required to support the government’s digital health ambitions and that sustainable funding and reimbursement mechanisms are now needed to enable widespread access to evidence-based digital therapeutics and remote patient care solutions.
Source: Adapted from transcript
Media access credit: Medical Technology Association of Australia (MTAA)
Note: Op Ed segments are opinions and comments on policies. They should be watched for awareness purposes only, and do not necessarily reflect the views held by Australian Health Journal.
-
A New Era in Primary Health Care Nursing
Coinciding with this year’s International Nurses Day, this week’s Federal Budget has had some significant outcomes for the primary health care, nursing workforce.
The Federal Budget delivered on 9th May 2023, APNA believes will strengthen Australia’s primary health care (PHC) system by addressing growing nursing shortages, seeing more nurses hired where they are needed, and better utilising the largest workforce in PHC of nearly 100,000 nurses to their full potential to reduce the pressure on the health system.
-
Clinical pain neuroscientist talks about how the brain processes pain information
Persistent pain affects one in five Australians and costs the nation an estimated $73 billion per year in health system costs, lost productivity and other financial costs.
Persistent pain also has debilitating personal costs – negatively impacting quality of life and the ability to engage in meaningful work and life activities.
Despite the enormity of this problem, very few effective treatments exist with most showing only small to moderate improvements. New treatments are desperately needed. The group believes the best way to create impactful change is to work with people with lived experience of persistent pain to devise solutions with them, not for them.
-
New treatment options under investigation for pelvic organ prolapse
Dr Shayanti Mukherjee, Research Group Head, Translational Tissue Engineering at the with her team at Hudson Institute of Medical Research is developing new ways to prevent and potential cure pelvic organ prolapse (POP). The technology aims to ultimately lead to safer and more effective treatment for women with pelvic organ prolapse (POP) using a woman’s own stem cells to boost the effectiveness of a degradable mesh.
